Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

OBJECTIVES: Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and superiority compared with efavirenz and ritonavir-boosted darunavir. We explored factors that predicted treatment success, the consistency...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffi, François, Rachlis, Anita, Brinson, Cynthia, Arasteh, Keikawus, Górgolas, Miguel, Brennan, Clare, Pappa, Keith, Almond, Steve, Granier, Catherine, Nichols, W. Garrett, Cuffe, Robert Liam, Jr, Joseph Eron, Walmsley, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284010/
https://www.ncbi.nlm.nih.gov/pubmed/25387312
http://dx.doi.org/10.1097/QAD.0000000000000519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284010/
https://www.ncbi.nlm.nih.gov/pubmed/25387312
http://dx.doi.org/10.1097/QAD.0000000000000519

Ejemplares similares